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Abstract
Zika virus (ZIKV) and Japanese encephalitis virus (JEV) are closely related to mosquito-borne flaviviruses. Japanese encephalitis (JE)
vaccine SA14-14-2 has been in the Chinese national Expanded Program on Immunization since 2007. The recent recognition of severe
disease syndromes associated with ZIKV, and the identification of ZIKV from mosquitoes in China, prompts an urgent need to
investigate the potential interaction between the two. In this study, we showed that SA14-14-2 is protective against ZIKV infection in
mice. JE vaccine SA14-14-2 triggered both Th1 and Th2 cross-reactive immune responses to ZIKV; however, it was cellular immunity
that predominantly mediated cross-protection against ZIKV infection. Passive transfer of immune sera did not result in significant
cross-protection but did mediate antibody-dependent enhancement in vitro, though this did not have an adverse impact on survival.
This study suggests that the SA14-14-2 vaccine can protect against ZIKV through a cross-reactive T cell response. This is vital
information in terms of ZIKV prevention or precaution in those ZIKV-affected regions where JEV circulates or SA14-14-2 is in
widespread use, and opens a promising avenue to develop a novel bivalent vaccine against both ZIKV and JEV.
Key points
• JEV SA14-14-2 vaccine conferred cross-protection against ZIKV challenge in mice.
• T cell immunity rather than antibody mediated the cross-protection.
• It provides important information in terms of ZIKV prevention or precaution.
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Introduction
Recently, Zika virus (ZIKV) has caused devastating outbreaks
of fetal congenital malformations in South and Central
America and now transmitted in more than 70 countries, in-
cluding many previously unaffected regions. ZIKV infection
during pregnancy increases the risk of neurological disorders
in newborns (Zhou et al. 2019), such as microcephaly. In
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adults, ZIKV causes Guillain-Barré syndrome and other neu-
rologic disorders (Mendez et al. 2017). So far, no specific
vaccine or antiviral for the prevention and treatment of Zika
has been licensed.
ZIKV is a member of the genus Flavivirus, family
Flaviviridae, which contains more than 70 viruses. Among
them, mosquito-borne flaviviruses such as Japanese encepha-
litis (JE) virus (JEV), dengue virus (DENV), ZIKV, yellow
fever virus (YFV), and West Nile virus pose a threat to half of
the world population and cause significant public health im-
pact in many developing countries (Guarner and Hale 2019).
The flavivirus genome consists of non-segmented single-
stranded positive-sense RNA, which encodes three structural
proteins including the capsid protein (C), the membrane pro-
tein (M), and the envelope protein (E), and seven non-
structural (NS) proteins (NS1, NS2a, NS2b, NS3, NS4a,
NS4b, and NS5). Within the same genus, these mosquito-
borne flaviviruses are antigenically related to various degrees
(Heinz and Stiasny 2017). Among them, JEV, ZIKV, and
DENV share more than 50% amino acid sequence identity
by pairs (Chang et al. 2017; Strauss and Strauss 2001). On
average, ZIKV shares a 55.6% protein sequence identity with
DENV and 56.1% with JEV (Chang et al. 2017).
Currently, several studies have indicated complex inter-
actions between DENV and ZIKV immunity (Breitbach
et al. 2019; Fowler et al. 2018; Pantoja et al. 2017; Slon-
Campos et al. 2019; Wang et al. 2019a; Zimmerman et al.
2018). Clinical data suggest that pre-existing DENV immu-
nity is partially protective against symptomatic ZIKV infec-
tion and against congenital ZIKV syndrome (Gordon et al.
2019; Pedroso et al. 2019). Earlier DENV infection also
probably partially protects against JE indicating the possi-
bility of a more general effect within the genus (Grossman
et al. 1974).
Previously, we demonstrated that JEV SA14-14-4 live at-
tenuated vaccine, an inactivated vaccine based on P3 strain,
and a JE DNA vaccine based on the premembrane and E
proteins, effectively elicited the production of cross-reactive
antibodies, cytokines, and cellular immune responses and gen-
erated cross-protection against four serotypes of DENV (Gao
et al. 2019; Li et al. 2016). However, little is known about
cross-reactivity between JEV and ZIKV. The geographic
overlap, possibility of sequential infection with JEV and
ZIKV, and widespread use of the JEV SA14-14-2 vaccine in
China indicate a need to understand the impact of pre-existing
immunity to JEV (acquired through either SA14-14-2 vacci-
nation or natural infection) on ZIKV infection. Therefore, in
this study, we aimed to evaluate the cross-reactivity and cross-
protection of JEV SA-14-14-2 vaccination against ZIKV in-
fection in a mouse model. Our findings suggest cross-
immunity between the JE vaccine and ZIKV and indicate a
need for further study in humans to address the role of JE
immunity in protection from ZIKV.
Materials and methods
Cells, viruses, vaccine, and mice
C6/36 cells (ATCC™ number CRL-1660) were cultured in
RPMI 1640 medium (Gibco, USA) supplemented with 10%
fetal bovine serum (FBS, Gibco, USA) at 28 °C. Vero cells
(ATCC™ number CCL-81) were cultured in minimal essen-
tial medium (MEM, Gibco, USA) supplemented with 5%
FBS at 37 °C. THP-1 cells (ATCC™ number TIB-202) were
cultured in RPMI 1640 medium supplemented with 10% FBS
at 37 °C. All cells were cultivated under a humidified atmo-
sphere of 5% CO2.
The JEV (Beijing-1 strain, GenBank accession number
L48961.1) and the ZIKV (SMGC-1 strain, GenBank
accession number KX266255) were propagated in C6/36 cell
cultures and stored at − 80 °C. JEV was kindly provided by
Dr. Kotaro Yasui (Department of Microbiology, Tokyo
Metropolitan Institute for Neuroscience, Tokyo, Japan).
ZIKV was kindly provided by Dr. George F. Gao (Institute
of Microbiology, Chinese Academy of Sciences, Beijing,
China). Virus titers were determined by plaque assay on
Vero cells under MEM with 1.2% methylcellulose overlay
medium. Propagated virus was harvested from the supernatant
of C6/36 cells infected with the virus, concentrated by 8%
polyethylene glycol precipitation, and purified from clarified
extracts by ultracentrifugation. The JE live attenuated vaccine
(SA14-14-2 strain) was produced by the Chengdu Institute of
Biological Products (China).
Female and male C57BL/6 mice and female Ifnar1-/- mice
were housed under specific pathogen-free conditions, and
C57BL/6 mice were bred to obtain neonatal mice. Adult fe-
male mice were used at 6 weeks of age, and neonatal Ifnar1-/-
mice were used between 24 h and 36 h after birth.
Mouse immunization
Six-week-old female adult mice were divided randomly into
vaccine and control groups. C57BL/6 and Ifnar1-/- mice in the
vaccine group were immunized intraperitoneally (i.p.) with
104 and 103 plaque-forming units (PFU) JEV SA14-14-2
strain, respectively, three times at 3-week intervals (Li et al.
2016). Control mice were injected with PBS following an
identical schedule.
Cross-reactive protection against ZIKV in SA14-14-2-
immunized Ifnar1-/- mice
Three weeks after the final vaccination, at 15 weeks of age, the
Ifnar1-/- mice were challenged i.p. with a lethal dose of JEV or
ZIKV (103 PFU for both). Body weight and mortality were
monitored daily for 14 consecutive days.
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Plaque reduction neutralization test
Sera were collected from the C57BL/6 mice 3 weeks after the
final vaccination. Neutralizing antibody (nAb) titers were detect-
ed by measuring plaque reduction neutralization titer (PRNT) as
previously reported (Wang et al. 2018, 2019b). Serum samples
were heated at 56 °C for 30 min to inactivate complement and
then twofold serially diluted from 1:10 to 1:1280. Diluted sera
were mixed 1:1 with virus suspension containing 50 plaque-
forming units (PFU) and incubated at 37 °C for 1 h. The mixture
was transferred to a confluent monolayer of Vero cells in a 24-
well plate and incubated at 37 °C for another 1 h. After washing,
the infected Vero cells were overlaid with MEM containing
1.2% methylcellulose followed by incubation at 37 °C for 5 to
8 days. Plaques were visualized by crystal violet counterstaining
and counted. The reciprocal highest serum dilution yielding a
50% reduction of the average number of plaques as compared
with the virus infection wells was calculated as the 50% neutral-
ization titer (PRNT50).
In vitro neutralizing and passive cross-protective ef-
fects of immune sera in neonatal C57BL/6 mice
Sera were collected from C57BL/6 mice 3 weeks after the
final vaccination. After heat inactivation, pooled sera were
mixed with either live JEV (Beijing-1 strain) or the ZIKV
(SMGC-1 strain) followed by incubation at 37 °C for 1 h.
Subsequently, 10 μl of serum/virus mixture containing 150
PFU of virus was gently injected intracerebally (i.c.) into neo-
natal C57BL/6 mice. The mice were monitored daily for body
weight and mortality for 31 consecutive days.
Enzyme-linked immunosorbent assay
To detect IgG antibodies and their subclasses, ELISA was
performed according to the method as previously described
(Wang et al. 2018). Sera were collected from C57BL/6 mice 3
weeks after the final vaccination. Each well of 96-well plates
was coatedwith purified viral particles (105 PFU) from JEV or
ZIKV and then blocked with 3% bovine serum albumin. Sera
from immunized mice were twofold serially diluted in PBS
(from 1:100 to 1:204,800), and IgG antibodies were measured
with goat anti-mouse secondary antibodies (1:4000, alkaline
phosphatase coupled, Abcam, USA) and substrate solution of
p-nitrophenyl phosphate (Sigma, USA). The optical density
(O.D.) at 405 nm was measured using an ELISA reader
(Thermo, USA). The reciprocal of the highest dilution that
yielded the O.D. value greater than half of the O.D. value of
corresponding control at 1:100 dilution was recorded as the
endpoint titer of IgG antibody (Wang et al. 2018).
To determine IgG subclasses, mouse sera (at 1:100 dilution)
were used as the primary antibodies; IgG1, IgG2a, IgG2b, and
IgG3 subsets were detected with goat anti-mouse secondary
antibodies (1:4000, alkaline phosphatase coupled, Abcam,
USA) and substrate solution of p-nitrophenyl phosphate; and
the levels of IgG subclasses were recorded as O.D. value at
405 nm.
Antibody-dependent enhancement assay
Three weeks after the final immunization, sera were collected
from C57BL/6 mice. Serially tenfold diluted sera were incu-
bated with JEV or ZIKV at a multiplicity of infection of 2 for
1 h at 37 °C before adding to THP-1 cells. Samples were
incubated for 2 h at 37 °C and gently shaken every 15 min.
Cells were centrifuged and washed three times, followed by
resuspension in fresh RPMI 1640medium and incubated for 3
days at 37 °C. Supernatants were collected, and viral titer
measured by plaque assay on Vero cells as described (Wang
et al. 2018). Fold enhancement was calculated by comparison
with viral titers in the absence of immune sera.
Enzyme-linked immunospot assays
Three weeks after the final immunization, the cytokines IL-2,
IL-4, and IFN-γ secreted by the splenocytes of C57BL/6 mice
were determined using enzyme-linked immunospot
(ELISPOT) kits (BD, USA) according to the manufacturer’s
instructions and the previous protocol (Wang et al. 2020,
2019c). In brief, mouse splenocytes were plated at 3 × 105/
well into 96-well filtration plates (Millipore, USA) pre-coated
with capture antibodies and stimulated with 5 μg/well purified
JEV or ZIKV particles for 60 h at 37 °C. After incubation with
biotinylated detection antibody, the spots were visualized by
adding streptavidin-horseradish peroxidase and 3-amino-9-
ethylcarbazole substrate, counted automatically with an
ELISPOT reader (CTL, USA) and analyzed by ImmunoSpot
software (version 5.1). Splenocytes coculturedwith concanav-
alin A served as a positive control, and those cultured with
RPMI 1640 medium served as a negative control.
Adoptive transfer and cross-reactive protection of
splenocytes from SA14-14-2-immunized C57BL/6
mice in Ifnar1-/- mice
Three weeks after the final vaccination, splenocytes were iso-
lated from the immunized C57BL/6 mice using lymphocyte
separation Percoll (Solarbio, China). A total of 3 × 106 lym-
phocytes was transfused retro-orbitally (r.o.) to female adult
Ifnar1-/- mice. After 24 h, the mice were challenged i.c. with a
lethal dose of either JEV (Beijing-1 strain, 104 PFU) or ZIKV
(SMGC-1 strain, 104 PFU). Body weight and mortality were
monitored daily for 14 consecutive days. Mice exhibiting
more than 25% loss in body weight were humanely eutha-
nized for ethical reasons.
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Statistical analysis
Statistical analyses were performed using SPSS statistics ver-
sion 17.0 (SPSS Inc., USA). Geometric mean titers (GMTs)
were calculated after the log transformation of reciprocal titers.
Weight changes were analyzed by repeated measures analysis
of variance. Kaplan-Meier survival curves were plotted and
evaluated statistically by the log-rank test. Others were ana-
lyzed using one-way analysis of variance. The results were
presented as means +/−/± standard deviation (SD), and the
difference between means is considered significant if P <
0.05. P values are denoted with an asterisk if P < 0.05, double
asterisk ifP < 0.01, and triple asterisk ifP < 0.001, respectively.
Results
Cross-protection against lethal ZIKV challenge in
immunocompromised mice
A number of studies have used Ifnar1-/- mice to evaluate the
effectiveness of vaccines despite the immunodeficiency of the
mice (Lecouturier et al. 2019; Shan et al. 2019). Although
Ifnar1-/- mice lack the innate type 1 IFN response, they retain
adaptive immunity but are highly susceptible to ZIKV (Dowall
et al. 2016), representing a suitable model for testing vaccine-
induced cross-protective adaptive immunity. First, we used this
model to determine whether JEV SA14-14-2 has a cross-
protective effect on ZIKV. Three doses of JE vaccine SA14-
14-2 were administrated to Ifnar1-/- mice, followed by challenge
with JEV or ZIKV 3weeks post the final immunization (Fig. 1a).
As expected, after JEV challenge, all mice inoculated with JEV
SA14-14-2 survived (6/6) during the observation period without
any weight loss (Fig. 1b, c). In contrast, the control mice showed
a rapid decrease 1 day post JEV challenge and all mice died by
the humane endpoint on day 3 post challenge. Interestingly,
SA14-14-2-vaccinated Ifnar1-/- mice were completely protected
(6/6) against ZIKV infection, as compared with PBS-treated
mice where 83.3% (5/6) mice succumbed to infection (Fig.
1b, c). Vaccinatedmicemaintained a normal bodyweightwhere-
as control mice showed significant weight loss (approximately
16%) and most of them died within 9 days (1/6 survival). These
data suggest that vaccination with SA14-14-2 in Ifnar1-/- mice
induced in vivo cross-reactive immunity, conferring effective
cross-protection against lethal ZIKV infection.
Cross-protection against ZIKV infection is not
mediated by SA14-14-2 immune sera
There is a clearly established role for nAb in protection from
flaviviruses. Therefore, in order to evaluate cross-reactive
neutralization of ZIKV induced by SA14-14-2 vaccination,
3 weeks after the final immunization, sera were collected from
C57BL/6mice and the nAb titers were assayed by PRNT (Fig.
2a). As expected, mice administered three doses of JEV
SA14-14-2 developed a high level of JEV-specific nAb, with
a GMT of 1:494 (Fig. 2b). In contrast, JEV SA14-14-2
antisera from the immunized mice failed to neutralize ZIKV,
Fig. 1 Cross-reactive protection against ZIKV in SA14-14-2-immunized
Ifnar1-/- mice. a Schedule. Female Ifnar1-/- mice were immunized three
times at 3-week intervals. Three weeks after the final vaccination, the
Ifnar1-/- mice were challenged i.c. with a lethal dose of JEV or ZIKV.
Bodyweight and mortality were monitored daily for 14 consecutive days.
b Percentage changes in body weight. Data were expressed as mean ±
SD. c Survival rate was shown as the percentage of survivors (n = 6).
Mice exhibiting more than 25% loss in weight were humanely euthanized
for ethical reasons. Each experiment was independently repeated three
times. Asterisk indicates P < 0.05; double asterisk indicates P < 0.01;
triple asterisk indicates P < 0.001
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and the PRNT50 titer of antisera was comparable to that of
controls. This result suggests that nAb elicited by JEV
SA14-14-2 yielded no neutralizing activity against ZIKV.
To further test whether JEV SA14-14-2 antisera would
cross-protect mice against ZIKV challenge in vitro, for exam-
ple, by a mechanism distinct from neutralization, immune sera
were harvested from SA14-14-2-vaccinated C57BL/6 mice
on week 3 after the final immunization. A serum/virus (JEV
or ZIKV) mixture was prepared and inoculated i.c. into naïve
neonatal C57BL/6 mice (Fig. 2a). Control sera from C57BL/6
mice injected with PBSwere included in the same experiment.
SA14-14-2 immune serum protected neonatal mice (8/8) from
JEV challenge, after which the mice exhibited steady growth
and development, manifesting a normal and continuous
weight increase, reaching 15.4 g at the end of observation
(Fig. 2c, d). In contrast, none of the neonatal mice (0/8) re-
ceiving non-immune sera survived JEV challenge and exhib-
ited severe growth delay, with an endpoint weight of only 2.0
g. ZIKV challenge was less pathogenic in this model than
JEV, with control mice (ZIKV infected receiving no sera)
developing subnormally but with indistinctive body weight
change (Fig. 2c). No effect of SA14-14-2 immune serum
could be detected in this experiment, and the terminal weights
of the mice receiving JEV SA14-14-2 immune serum and
control mice were 9.8 g and 9.1 g, respectively. Survival in
the two groups was also the same, 10.0% (1/10) in mice
incoculated with a mixture of SA14-14-2 immune sera and
ZIKV and 8.3% in mice injected with control mixture (1/12,
Fig. 2c, d). Although SA14-14-2 immune sera did slightly
extend the median survival of neonatal ZIKV-challengedmice
(22.0 days vs. 15.0 days), this effect was not significant by the
log-rank test. These data suggest a potent JEV-specific pro-
tective effect of SA14-14-2 immune sera, but no cross-
protection from ZIKV infection, consistent with the nAb data.
Presence of cross-reactive IgG antibody and its mul-
tiple subclasses in response to ZIKV induced by SA14-
14-2 vaccination
While we could detect no protective role of cross-reactive
antibody against ZIKV infection from SA14-14-2 immune
sera, we sought to determine whether there was any binding
to ZIKV, as cross-reactive binding but non-neutralizing anti-
bodies have been described (Dejnirattisai et al. 2016). Thus, to
determine the presence of JEV-specific and ZIKV cross-
reactive IgG antibody and its subclasses, including IgG1,
IgG2a, IgG2b, and IgG3, induced by SA14-14-2 vaccination,
sera were collected 3 weeks after the last immunization from
C57BL/6 mice and analyzed by ELISA (Fig. 3a). Levels of
both JEV-specific and ZIKV cross-reactive IgG antibodies
Fig. 2 Cross-reactive nAb responses in mouse sera. a Schedule. Female
adult C57BL/6 mice were immunized as previously described. Sera were
collected and mixed with either JEV (Beijing-1 strain) or ZIKV (SMGC-
1 strain). Then, serum/virus mixture was gently injected i.c. into neonatal
C57BL/6 mice. b Serum cross-reactive nAb titers assayed by PRNT50 (n
= 7). NAb titers are expressed as GMT + SD. c, d In vitro neutralizing and
passive cross-protective effects of immune sera (n = 8, 8, 10, 12, respec-
tively). The mice were monitored daily for body weight and survival rate
for 31 consecutive days. c Body weight was expressed as mean ± SD. d
Survival rate was shown as the percentage of survivors. Triple asterisk
indicates P < 0.001; NS, non-significant
Appl Microbiol Biotechnol
were higher in the sera of immunized mice than those in cor-
responding controls (1:60,887 vs. 1:519 and 1:1345 vs. 1:436
endpoint titers, respectively, Fig. 3b), suggesting the induction
of a cross-reactive humoral immune response to ZIKV.
Furthermore, to informatively characterize the profile of
cross-reactive IgG antibodies induced by SA14-14-2-vaccina-
tion, IgG1, IgG2a, IgG2b, and IgG3 subclasses in immune
sera were measured (Fig. 3c). It is known that isotype
switching to IgG1 is promoted by a Th2 response, whereas
switching to IgG2a, IgG2b, and IgG3 is promoted by a Th1
response (Germann et al. 1995). Our data show that IgG1,
IgG2a, and IgG2b were all detected after vaccination, but
IgG3 was not induced. These data suggest that SA14-14-2
vaccination could induce a response with both Th1 and Th2
components.
SA14-14-2 immune sera induce antibody-dependent
enhancement in vitro
Antibody-dependent enhancement (ADE) occurs when the
titer or neutralization potential of serum is too low to achieve
complete neutralization, but the antibody is still able to bind to
the virus, which then promotes entry into Fc receptor–bearing
cells, which are permissive for viral replication. The effect is
common among flaviviruses (Langerak et al. 2019).
Therefore, in order to determine whether the SA14-14-2 im-
mune sera could promote ADE of ZIKV infectivity in vitro,
we exposed FcγRI/II-bearing cell line THP-1 to ZIKV in the
presence or absence of SA14-14-2 immune sera. We observed
dose-dependent enhancement of infection from a dilution of
1:100, which peaked at 1:10,000 dilution, with ZIKV infec-
tion enhancement up to 79.7-fold (Fig. 3d). In contrast, sera
from control mice did not significantly enhance the infectivity
of ZIKV, although modest enhancement at a dilution of
1:10,000, likely due to non-specific effect. Meanwhile, when
THP-1 cells were infected in the presence of the SA14-14-2
immune sera, we found that they also yielded a 17.0-fold
greater infection of JEV at a dilution of 1:10,000 than those
in the absence of sera (Fig. 3d). This homotypical enhance-
ment is most likely the result of sub- or non-neutralizing titer
of serum dilution. As expected, the control sera did not obvi-
ously enhance JEV infection. In summary, the result demon-
strates that cross-reactive anti-JEV antibodies can promote
ADE of ZIKV, at least in vitro.
Multiple cross-reactive cytokine responses to ZIKV
Having provided indirect evidence that both Th1 and Th2
responses were made following SA14-14-2 vaccination and
that these responses could cross-react with ZIKV, albeit not
with protective nAb, we sought to determine the nature of the
T helper response after SA14-14-2 vaccination. Three weeks
after the third and final immunization, splenocytes were col-
lected from the C57BL/6 mice. The levels of splenocyte-
derived IL-2, IL-4, and IFN-γ were determined by
ELISPOT assay (Fig. 4). Notably, when pulsed with ZIKV
antigen, splenocytes from SA-14-14-2-immunized mice
responded by making all three cytokines, although the levels
Fig. 3 Cross-reactive IgG and its subclass responses and ADE in mouse
sera. a Schedule of mouse immunization and serum collection. Female
adult C57BL/6 mice were immunized three times at 3-week intervals.
Sera were collected 3 weeks after the final immunization. b Cross-
reactive IgG responses detected by ELISA (n = 7). Ab titers are recorded
as GMT + SD. c Cross-reactive IgG subclass responses determined by
ELISA (n = 7). d ADE in sera measured by plaque forming (n = 7 per
dilution). Asterisk indicates P < 0.05; double asterisk indicates P < 0.01;
triple asterisk indicates P < 0.001
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were lower when compared with responses of SA-14-14-2-
immune splenocytes upon stimulation with JEV antigen. IL-2
and IFN-γ are predominant markers of the Th1 response; IL-4
expression is defined as a marker of the Th2 response. The
results indicated that either the Th1- or the Th2-type cross-
reactive immune response against ZIKV was evoked by the
administration of the JEV SA-14-14-2 vaccine.
Cell-mediated immunity as a potential mechanism of
cross-protection against ZIKV
Although multiple cytokines can be produced under ZIKV
antigen stimulation, it was unclear whether cellular immunity
was indispensable or essential for the in vivo cross-reactive
protection. Therefore, adoptive transfer of immune
splenocytes from SA14-14-2-immunized C57BL/6 mice into
naïve Ifnar1-/- recipient mice was performed 3 weeks after the
final immunization, followed by viral challenge with a lethal
dose of JEV or ZIKV (Fig. 5a). After JEV challenge, mice
receiving splenocytes derived from the control group showed
marked and up to 26.7% body weight loss, and all mice died
(0/6) within 9 days, whereas 100% (6/6) of mice receiving
SA14-14-2-immune splenic lymphocytes survived without
obvious weight change (Fig. 5b, c), suggesting that a protec-
tive prototype of splenocytes activated by SA14-14-2 was
successfully established. Meanwhile, while naïve Ifnar1-/- re-
cipient mice in the control group showed high susceptibility to
ZIKV infection with weight loss of 17.0% and only 16.7%
(1/6) survival rate, virtually 83.3% (5/6) of mice infused with
SA14-14-2-immune lymphocytes survived the lethal ZIKV
challenge with only a weight loss of 5.8% (Fig. 5b, c).
Taken together with our nAb data, this result demonstrated
that a cell-mediated cross-reactive response induced by
SA14-14-2 immunization was protective against subsequent
ZIKV infection.
Discussion
It is becoming increasingly apparent that the pre-existing im-
munity triggered by primary flavivirus infection or vaccina-
tion can induce immunological cross-reactivity to secondary
exposure with a genetically and antigenically closely related
flavivirus. Immunological cross-reactions have been implicat-
ed in both protection and pathology, and there is some con-
troversy on the consequences of the outcome of infection. An
in vitro study showed an enhancement of ZIKV replication in
the presence of DENV antibodies (Dejnirattisai et al. 2016).
However, clinical cohort and case-control studies of individ-
uals in dengue endemic regions suggest the opposite that pre-
existing dengue immunity reduces the risk of symptomatic
ZIKV infection and congenital ZIKV syndrome (Gordon
et al. 2019; Pedroso et al. 2019; Rodriguez-Barraquer et al.
2019). Pantoja et al. studied the effects of pre-existing DENV
immunity on ZIKV infection in vivo in rhesus macaques and
confirmed that the previous exposure to DENV did not result
in the enhancement of ZIKV pathogenesis (Pantoja et al.
2017). Intriguingly, there has been relatively little ZIKV in-
fection reported in Asia, and it has been suggested that cross-
reactive T cell responses generated by -borne flaviviruses, of
which the principal agent is JEV, has limited ZIKV spread in
Asia (Gaunt et al. 2019).
Fig. 4 Cross-reactive cytokine
responses in mouse splenocytes. a
Schedule. Three weeks after the
final immunization, splenocytes
from adult C57BL/6 mice were
collected. b The cytokines IL-2,
IL-4, and IFN-γ secreted by
splenocytes were determined
using ELISPOT (n = 7). The
numbers of cytokine-positive
cells are reported as the mean
SFU/3 × 105 splenocytes + SD.
Asterisk indicates P < 0.05; dou-
ble asterisk indicates P < 0.01;
triple asterisk indicates P < 0.001
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Previously, we found that live attenuated JE vaccine SA-
14-14-2 conferred cross-reactive nAbs which contributed to
the cross-protection against DENV challenge (Li et al. 2016).
In contrast to this result, in this study, mice immunized with
SA14-14-2 showed a cross-reactive IgG antibody response to
ZIKV without the presence of neutralizing activity (Figs. 2b
and 3b). Although the ADE in SA14-14-2 immune sera was
detected in vitro (Fig. 3d), we found no evidence that this
resulted in a harmful effect; indeed, in subsequent ZIKV chal-
lenge, SA14-14-2 vaccination slightly lengthened the median
survival (Fig. 2d). This is an important result, suggesting that
cross-reactive antibodies from SA14-14-2 vaccination are not
pathogenic in vivo, because many people in Asia have re-
ceived inactivated JE vaccine which will generate anti-JEV
nAb but may not contain many of the cross-reactive T cell
epitopes, which lie in the NS proteins (Turtle et al. 2016).
Here, we use neonatal C57BL/6 mice instead of neonatal mice
because the former is susceptible to ZIKV and can mimic the
signs (Wang et al. 2018). Although the SA14-14-2 vaccine
triggered both Th1 and Th2 responses (Figs. 4b and 3c), adop-
tive splenocyte transfer was superior to serum transfer in pro-
tection against ZIKV infection, implying a strong correlation
between SA14-14-2-induced cellular immunity and the ZIKV
cross-protective capacity. However, the limitation in this
study is that we did not elucidate the functional components
which are cross-protective by further sorting of splenocytes
for adoptive transfer, such as purified T cells or their subpop-
ulations (CD8+ or CD4+ alone), or cross-reactive memory B
cells. Furthermore, we did not determine whether the cross-
reactive nAb response was present in recipient mice trans-
ferred with SA14-14-2-immune splenocytes, although this is
unlikely to change our primary conclusions.
Traditionally, based on cross-neutralizing activity,
f laviviruses have been sub-divided into dis t inct
serocomplexes. Cross-neutralization between different
serocomplexes is usually not observed (Heinz and Stiasny
2017). The flavivirus E protein is the principal antigen against
which the nAb response is directed. The extent of cross-
neutralization correlates with the amino acid sequence identity
of E protein: when the sequence identity in E protein is less
than 40%, cross-neutralization is lost (Stiasny et al. 2006).
JEV and ZIKV belong to distinct serocomplexes; although
the homology of the E protein amino acid sequence between
the JEV SA14-14-2 strain and the ZIKV SMGC-1 strain was
53.4%, the distinct epitopes in E proteins of JEV and ZIKV
within different flaviviruses that dominate antibody responses
are presumably responsible for the unavailable cross-
neutralization (Dowd and Pierson 2011). For the sequence
homology of the E protein, ZIKV is more closely related to
the DENV than to the JEV serocomplex (Heinz and Stiasny
2017). However, most B cell epitopes are conformational
(Sanchez-Trincado et al. 2017), and therefore, sequence ho-
mology may not fully reflect “relatedness” as measured by
cross-reactive humoral responses. Interestingly, one structural
model of the relatedness of flavivirus surface topology in fact
placed ZIKV and JEV closer to each other than either was to
Fig. 5 Adoptive transfer of splenocytes from SA14-14-2-vaccinated
C57BL/6 mice and cross-protection of splenocytes in Ifnar1-/- mice. a
Schedule. Splenic lymphocytes (3 × 106 cells per mouse) collected 3
weeks post final immunization were adoptively transferred r.o. to naïve
adult mice, and 1 day later mice were challenged with a lethal dose of
either JEV or ZIKV. As a control, splenic lymphocytes from PBS-treated
mice were transferred to naïve mice prior to challenge. Results were
evaluated for b body weight change and c survival rate of mice 14 con-
secutive days post challenge (n = 6). Mice exhibiting more than 25% loss
in weight were humanely euthanized for ethical reasons. Each experiment
was independently repeated three times. Results are expressed as mean ±
SD. Asterisk indicates P < 0.05; double asterisk P < 0.001
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DENV (Wang et al. 2017). Nevertheless, despite this structur-
al similarity, this did not account for protection in the model
we describe here.
In contrast, NS proteins among flaviviruses are more con-
served with up to 68.0% identity than structural proteins.
Weiskopf et al. indicated that, following heterologous DENV
infection, memory CD8+ T cells expanded that recognized con-
served NS proteins (Weiskopf et al. 2014). In fact, NS3 and
NS5 represent the main targets of the CD8+ T cell response to
flaviviruses (Dos Santos et al. 2019; Rivino and Lim 2017).
One study reported more cross-reactive T cell responses to full-
length NS3 helicase because of higher sequence homology
than that to the protease region alone (Herrera et al. 2018).
Also, a homologous analysis based on the NS5 protein would
place ZIKV closer to the JEV serocomplex than to DENVs
(Barba-Spaeth et al. 2016). In our study, we hypothesize that
it is the cross-reactive response to shared T cell epitopes in the
NS proteins that contributes to protection mediated by the
adoptive transfer of immune splenocytes.
In a mouse model, CD8+ T cells can mediate protection
against ZIKV (Dos Santos et al. 2019). DENV-specific
cross-reactive CD8+ T cells can also protect (Wen et al.
2017), and similar responses are detected in humans, where
cross-reactive CD8+ T cells specific for DENV display anti-
ZIKV effector potential toward ZIKV, mediating direct cytol-
ysis (Lim et al. 2018). JEV and ZIKV share 63.9% and 68.0%
homology in NS3 and NS5, respectively. Our findings are
consistent with a cross-reactive CD8+ T cell mediating protec-
tion, but characterization of the key components responsible
for cross-protection in splenic lymphocytes and identification
of JEV/ZIKV cross-reactive epitopes warrant further
investigation.
Since 2007, China has included a two-shot schedule of the
JEV SA14-14-2 vaccine into the national Expanded Program
on Immunization. Children under the age of 13 and even older
children in some provinces of China have pre-existing JEV
immunity. It should be noted that, according to the established
schedule, children received the SA14-14-2 vaccine at 8
months and 2 years of age, but three immunizations in mice
were performed in this study, as per the earlier studies (Li et al.
2016). In order to ensure comparability with what humans
receive, future studies may need to test various dosing
regimens.
Fu et al. and Xiao et al. identified ZIKV in mosquitoes in
Guizhou province and Yunnan province (Fu et al. 2017; Xiao
et al. 2018), indicating that ZIKV is present in China.
Therefore, it is inevitable that JEV and ZIKV co-circulate.
The identification of ZIKV presents new challenges for pre-
vention and control because of its severe consequences in
pregnancy (Grazel and Harris-Haman 2018) and prompts an
urgent need to clarify the mechanisms underlying such cross-
protective immunity, which will inform the strategy of
developing safe and effective vaccines targeting both viruses,
with appropriately balanced B cell and T cell antigens.
A shortcoming of our work is that we have not performed
more detailed mechanistic experiments to determine which
components of the cellular response are responsible for medi-
ating protection. A further hypothesis that remains to be ex-
plored is whether cellular immunity to the JE vaccine results
in a faster ZIKV-specific nAb response, by providing T cell
help to ZIKV specific B cells by cross-reactive CD4+ T cells.
Detailed mapping and specific epitope cross-reactivity studies
of the T cell response to JE vaccine SA14-14-2 in this model
would address this. This, along with a more detailed definition
of the mediators expressed by cross-reactive T cells, or other
protective mechanisms, should be the priorities for ongoing
work.
In conclusion, the results of our study demonstrated that
JEV SA14-14-2 elicited effective cross-protection against
ZIKV in mice. Our results indicate the potential for the wide-
spread use of the vaccine, especially in those co-circulating
countries. Moreover, this study will provide important infor-
mation in terms of ZIKV prevention or precaution.
Furthermore, it is worthwhile to identify common epitopes
for the future development of a novel bivalent vaccine based
on T cell against both JEV and ZIKV.
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